The conversation around the future of depression treatment continues to evolve as new advances emerge across the field. Recent reporting on the future of interventional psychiatry from Medscape highlights a late-stage investigational therapy that could significantly change how ketamine-based treatments are delivered to patients with treatment-resistant depression.
A Persistent Challenge In Depression Care
Treatment-resistant depression remains one of the most difficult conditions in psychiatry. Many patients fail to achieve meaningful improvement despite trying multiple antidepressants, psychotherapy, and other evidence-based interventions.
Ketamine and esketamine have introduced a fundamentally different treatment paradigm by offering rapid antidepressant effects. Unlike conventional antidepressants that may require weeks to demonstrate benefit, ketamine-based therapies can produce noticeable symptom improvements within hours or days.
However, these treatments come with important limitations. Dissociative symptoms, cardiovascular effects, abuse concerns, and mandatory clinical monitoring requirements have restricted broader access. Many patients must travel repeatedly to specialized clinics and remain under observation after treatment.
A New Oral Approach To Ketamine Delivery
Researchers and developers are now evaluating KET01, an extended-release oral ketamine formulation designed to provide antidepressant benefits while reducing some of the challenges associated with currently available options.
Rather than producing a rapid spike in blood concentration, the tablet slowly releases ketamine over several hours. This prolonged delivery model is intended to reduce acute cardiovascular changes and dissociative effects while maintaining antidepressant activity.
The long-term goal is particularly notable. If safety and effectiveness are confirmed in larger studies, the medication could potentially be administered at home rather than exclusively in supervised clinical settings.
Why The Study Design Matters
One of the most interesting aspects of this development is its focus on pharmacokinetics rather than simply creating another ketamine product.
The extended-release design aims to alter how ketamine moves through the body. Investigators report that the formulation generates lower peak ketamine concentrations while increasing exposure to downstream metabolites such as hydroxynorketamine.
This distinction is important because researchers continue to debate which biological pathways are primarily responsible for ketamine’s antidepressant effects.
If antidepressant benefits can be maintained while minimizing adverse experiences, treatment accessibility could improve substantially.
Extended-Release Ketamine For Treatment-Resistant Depression Shows Early Promise
Early phase 2 studies have produced encouraging findings. Investigators reported rapid antidepressant effects among participants receiving the higher dose regimen. Additional research suggested lower dissociative symptom scores compared with intranasal esketamine.
Researchers also observed reduced acute increases in heart rate and blood pressure, findings that support the theoretical advantages of slower drug release.
At the same time, experts emphasize caution. Fewer than 200 patients have received the investigational treatment thus far, meaning larger studies are necessary before definitive conclusions can be drawn.
The Debate Over Subjective Experience
An important scientific question remains unresolved.
Many clinicians and researchers have observed that ketamine experiences often involve altered states of consciousness, emotional breakthroughs, and shifts in perspective. Some patients describe profound feelings of connection, meaning, or psychological insight during treatment.
Whether these experiences contribute directly to antidepressant outcomes remains controversial.
If an extended-release formulation reduces or eliminates these subjective effects, researchers must determine whether therapeutic benefits remain equally durable over time. The answer could influence how future ketamine therapies are developed and evaluated.
Balancing Accessibility And Safety
The possibility of at-home administration creates both opportunities and concerns.
Greater convenience could expand access for patients living far from specialty clinics and reduce treatment burdens for those requiring maintenance therapy. This could be particularly valuable in healthcare systems facing workforce shortages and growing mental health demands.
Yet concerns about misuse, dose escalation, and long-term safety remain. Experts have warned that unsupervised ketamine use may increase risks related to tolerance, cognitive effects, and substance misuse in vulnerable individuals.
Future studies will need to clarify how patients can be monitored effectively while preserving the convenience of home-based treatment.
What Comes Next For The Field
Extended-release ketamine represents more than a new formulation. It reflects a broader effort to make interventional psychiatric treatments safer, more scalable, and more accessible.
Whether KET01 ultimately reaches routine clinical practice remains uncertain. However, the research highlights a growing focus on improving delivery systems alongside therapeutic mechanisms.
For patients with treatment-resistant depression, that shift could prove just as important as the discovery of new treatments themselves.
Citations
Scherer L. “Is At-Home, Extended-Release Ketamine Coming to Market Soon?” Medscape, June 2026. https://www.medscape.com/viewarticle/home-extended-release-ketamine-coming-market-soon-2026a1000iok?utm_source=chatgpt.com
SPRAVATO (Esketamine) Prescribing Information
Explore more at https://www.interventionalpsychiatry.org/